Typical dosing protocols used in research settings have varied considerably, with reported ranges from 5-10 mg administered subcutaneously for periods of 10-20 days, often followed by several months without treatment
Products have not been evaluated by Health Canada and are not intended to diagnose, treat, cure, or prevent any disease
The synergy might arise from the combined action of GHK-Cu in stimulating glycosaminoglycan production, promoting collagen synthesis, and HA's role in reducing collagen degradation by scavenging reactive oxygen species and inhibiting matrix metalloproteinases
Sager T, Wolfarth M, Keane M, Porter D, Castranova V, Holian A
$59.00 Save 2.6% when paying via Zelle/Venmo or ACH at checkout 1% of every order supports Childrens Hospital & Disabled American Veterans
I was diagnosed with PA nearly 3 years ago